Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D7UW0X
|
|||
| Drug Name |
PRAX-562
|
|||
| Synonyms |
Relutrigine; PRAX-562; 2392951-29-8; 3-[Ethoxy(difluoro)methyl]-6-[5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl]-[1,2,4]triazolo[4,3-a]pyrazine; relutrigine [INN]; AW5C5XHM4W; PRAX562; SCHEMBL23132181; GTPL12643; BFXBSYMVTNEFRF-UHFFFAOYSA-N; EX-A7203; HY-148792; CS-0641132; 1,2,4-TRIAZOLO(4,3-A)PYRAZINE, 3-(ETHOXYDIFLUOROMETHYL)-6-(5-FLUORO-6-(2,2,2-TRIFLUOROETHOXY)-3-PYRIDINYL)-; 3-(ethoxydifluoromethyl)-6-[5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3- yl][1,2,4]triazolo[4,3-a]pyrazine
Click to Show/Hide
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Epileptic encephalopathy [ICD-11: 8A62] | Phase 2 | [1] | |
| Company |
Praxis Precision Medicines Boston, MA
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C15H11F6N5O2
|
|||
| Canonical SMILES |
CCOC(C1=NN=C2N1C=C(N=C2)C3=CC(=C(N=C3)OCC(F)(F)F)F)(F)F
|
|||
| InChI |
InChI=1S/C15H11F6N5O2/c1-2-28-15(20,21)13-25-24-11-5-22-10(6-26(11)13)8-3-9(16)12(23-4-8)27-7-14(17,18)19/h3-6H,2,7H2,1H3
|
|||
| InChIKey |
BFXBSYMVTNEFRF-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05818553) A Phase 2,Double-Blind,Randomized Clinical Trial to Explore the Safety,Tolerability,Efficacy, and Pharmacokinetics of PRAX-562 in Pediatric Participants With Developmental and Epileptic Encephalopathies Followed by Open-Label Extension(OLE). U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.